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a b s t r a c t
A library of novel pyridylchalcones were synthesised and screened against Trypanosoma brucei rhode-
siense. Eight were shown to have good activity with the most potent 8 having an IC50 value of 0.29 mM.
Cytotoxicity testing with human KB cells showed a good selectivity proﬁle for this compound with a
selectivity index of 47. Little activity was seen when the library was tested against Leishmania donovani.
In conclusion, pyridylchalcones are promising leads in the development of novel compounds for the
treatment of human African trypanosomiasis (HAT).
© 2017 Elsevier Masson SAS. All rights reserved.
1. Introduction
Human African trypanosomiasis (HAT), also known as sleeping
sickness, is a parasitic disease transmitted by the bite of tsetse ﬂies.
It occurs in 36 countries in sub-Saharan Africa, where millions of
people are at risk of infection [1e3]. HAT is caused by 2 sub-species
of Trypanosoma brucei and exists as a chronic infection with T. b.
gambiense or as an acute infection with T. b. rhodesiense. Untreated,
both forms are usually fatal [1e3]. There are two clinical stages in
the progression of HAT. The ﬁrst corresponds to the multiplication
of the parasites in the blood and lymphatic system. The second
occurs when these cross the blood-brain barrier to infect the cen-
tral nervous system causing neurological symptoms to appear.
Stage 1 can be treated with pentamidine and suramin whereas
melarsoprol, eﬂornithine, and their combinations with nifurtimox
are the only treatments for stage 2. All of these drugs suffer from
serious drawbacks including low efﬁcacy, severe toxic side effects
and the need for parenteral administration [1e3]. With no vaccine
available and limited therapeutic alternatives the continuing
emergence of drug resistance is seen as a major public health
problem [4]. An urgent need exists for the development of more
effective, less toxic and orally available treatments for this neglec-
ted tropical disease.
Chalcones (1,3-diphenyl-2-propen-1-ones) are a major class of
natural products often found in edible plants. They have received
considerable attention due to their wide range of biological actions
and have been used as a scaffold in the development of anticancer,
antioxidant, antiangiogenic, and anti-inﬂammatory agents [5]. A
number of natural and synthetic chalcones have been shown to
possess anti-parasitic activities including licochalcone A 1, a natural
prenylated chalcone isolated from liquorice root (Glycyrrhiza gla-
bra), and a potent anti-leishmanial agent [6]. However, the thera-
peutic use of chalcones has been limited due to their poor
bioavailability and rapid metabolic clearance from biological sys-
tems [7]. Nevertheless, hybrid molecules incorporating the chal-
cone moiety are emerging as promising leads for targeting
Leishmania and Trypanosoma species [8e11]. For example, the
chalcone-benzoxaborole hybrid 2 gave 100% mouse survival rate
and complete elimination of parasites in a T. b. bruceimurine model
[9].
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Pyridylchalcones, such as 3 and 4, have been found to exhibit
both antimalarial and anti-leishmanial activity [6, 11, 12, 13].
However, there are no examples of them being tested against Try-
panosoma brucei. With the antitrypanosomal activity of chalcone
hybrids in mind [8e11], we were intrigued to determine whether
pyridylchalcones would also be active against this target. It was
anticipated that pyridyl analogues would exhibit the same low
toxicity shown by compounds containing the chalcone nucleus but
with improved bioavailability [14]. The introduction of a pyridine
group will reduce the lipophilicity of the molecule and increase
water solubility, both of which should ease formulation. In addi-
tion, lowering the lipophilicty of a chalcone and the inclusion of a
heterocyclic A-ring has been associated with an increase in anti-
parasitic activity [15] (see Fig. 1).
We report here the synthesis and in vitro evaluation of a series of
novel pyridylchalcones against T. b. rhodesiense and L. donovani.
Their cytotoxicity against human KB cells was also determined to
establish their selectivity proﬁle.
2. Chemistry
Attempts to prepare the 3-(3-pyridyl)chalcone 8 using standard
Claisen-Schmidt conditions with 2 equivalents of aqueous sodium
hydroxide inmethanol yielded an unexpected result [16]. Instead of
the desired chalcone, recrystallization from ethanol afforded the
diketone 7 in 25% yield (Scheme 1). This product presumably re-
sults from conjugate addition of the enolate of 3-
bromoacetophenone to the previously formed chalcone. Similar
results were obtained when using 3-chloroacetophenone and 4-
chloroacetophenone. To our knowledge this unusual reactivity
has not previously been reported for 3-pyridinecarboxaldehyde 5,
although it has been observedwith both 2-pyridinecarboxaldehyde
and 2-quinolinecarboxaldehyde when reacted with acetophenone
under similar conditions [17]. The addition of one equivalent of
pyridine to these reactions was found to prevent this conjugate
addition. This was thought to be due to the pyridine competing
with the aldolate nitrogen for chelation of the metal ion in the
intermediate. Unfortunately, this result was not repeated when one
equivalent of pyridine was added to our reaction.
Bhagat et al. report good yields of chalcone with all three iso-
mers of pyridinecarboxaldehyde when reacted with 4-
methoxyacetophenone and 10% lithium hydroxide monohydrate
in ethanol [18]. Using these conditions, we obtained 8 in a disap-
pointing yield of 39%. It was clear from TLC that 7 was still being
formed during this reaction. This proved difﬁcult to remove by
recrystallization from ethanol, and column chromatography was
required to obtain pure 8. In a bid to improve yields and simplify
puriﬁcation we investigated the use of potassium hydroxide as a
catalyst in 1,4-dioxane. This couple has been found to give good
yields of quinoline-2-one based chalcones which had proved
difﬁcult to prepare using other conditions [19]. However, with 1.6
equivalents of potassium hydroxide we again obtained a mixture of
8 and 7. Maintaining 1, 4-dioxane as the solvent but changing the
base to lithium hydroxidemonohydarate proved the solution to our
problems with 8 being obtained in 80% yield after recrystallization
from ethanol. TLC showed little or no diketone formation. This
method proved suitable for the synthesis of a range of pyr-
idylchalcones (Scheme 2,Table 1) in high yield.
3. Results and discussion
The activity of our chalcones against T. b. rhodesiense (STIB900)
was determined using the Alamar blue growth inhibition assay
[20]. Their cytotoxicity against human KB cells was also obtained
in vitro (Table 1) allowing the calculation of a selectivity index (SI)
for each compoundwhere: SI¼ IC50 (KB cells)/IC50 (T. b. r). Of the 17
compounds synthesised, 8 showed good activity against T. b. rho-
desiense (IC50 < 0.2 mg/mL), 8 moderate activity (IC50 0.2e3 mg/
mL) and 1 was inactive (IC50 > 3 mg/mL). The most active com-
pound, with an IC50 value of 0.29 mM, was 8 which contained a 3-
pyridyl A-ring and a 3-bromophenyl B- ring. This compound also
showed good selectivity with an SI of 47. Although it was difﬁcult to
establish a clear structure activity relationship, certain trends were
apparent. The presence of a pyridyl A-ring appears to be important
for high activity. When this was replaced by a phenyl, as in 9, the
activity dropped to 0.96 mM. The position of the nitrogen in the
pyridine ring does not seem to be as crucial with the 2-pyridyl
derivative 18 still having reasonable activity (IC50 ¼ 0.40 mM). The
4-pyridyl derivative 17 had a lower IC50 value of 0.65 mM but was
still considered active. Modifying the B-ring while keeping a 3-
pyridyl A-ring can have a signiﬁcant effect on activity. This was
particularly apparent in 13 and 14 which both have substituents at
the 2-position in the B-ring. The latter with a methoxy group shows
only moderate activity with an IC50 value of 1.14 mM, while the
former with a bromo is our only inactive compound. Moving the
bromo group in 8 to the para position produced a slight reduction in
activity with 12 having an IC50 of 0.34 mM. A more signiﬁcant
changewas evident in 20where the bromo group in 8was replaced
by a chloro resulting in a doubling of the IC50 value to 0.62 mM.With
a methoxy group at the meta position in ring B, 11 showed
reasonable activity (IC50 0.41 mM) but had a relatively low SI of 6.
Fig. 1. Anti-parasitic chalcones.
Scheme 1. Reagents and conditions: (i) NaOH(aq), MeOH, 0 C then RT (25%). (ii)
LiOH$H2O, 1,4-dioxane, RT (80%).
Scheme 2. Reagents and conditions: (i) LiOH$H2O, 1,4-dioxane, RT.
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Moving the methoxy group to the para position signiﬁcantly
reduced activity with 15 having an IC50 of 0.94 mM. The only other
derivatives with an electron releasing group at this position, 16
(3,4-dimethoxy) and 21 (3,4-methylenedioxy), both exhibited only
moderate activity suggesting that electron releasing groups in the
B-ring are not conducive to high activity. The phenyl derivative 10
and its 3, 4-diﬂuoro analogue 22 were both active with the same
IC50 value of 0.72 mM. The phenolic chalcone 23 had moderate ac-
tivity with an IC50 value of 1.15 mM. Taken in conjunction with our
other results this could suggest that high activity is favoured by a
hydrophobic group at the 3-position in the B-ring. A 3-pyridyl
group in the B-ring is not optimum for activity with 19 and 24
giving only moderate IC50 values of 0.69 and 1.02 mM respectively.
The diketone 7 was found to be inactive.
In view of the literature precedent [11, 12] and our above results
with T. b. rhodesiense we decided to screen our compound library
against Leishmania donovani [21]. Using HU3 intracellular amasti-
gotes at 30 mM only 8, 9, 12 and 20 showed any activity, with 39.7,
13.8, 11.6 and 2.7% inhibition respectively. At 10 mM no inhibition
was observed. Thus, although a number of our derivatives showed
promise as potential antitrypanosomal agents they appear to have
little activity against Leishmania.
4. Conclusion
Initial attempts to prepare 3-pyridylchalcones using standard
Claisen-Schmidt conditions with sodium hydroxide were unsuc-
cessful resulting in the formation of a diketone. This problem was
overcome by the use of lithium hydroxide monohydrate as base in
1, 4-dioxane. Of the 17 derivatives synthesised eight were shown to
have good activity against T. b. rhodesiense with the most active 8
having an IC50 value of 0.29 mM. This compound showed good
selectivity with an SI of 47. Little activity was observed when the
library was evaluated against L. donovani. In conclusion, pyr-
idylchalcones are promising leads in the development of novel
compounds for the treatment of HAT.
5. Experimental section
5.1. Synthetic chemistry
5.1.1. General
All solvents and chemicals were used as purchased without
further puriﬁcation. The 1H and 13C-NMR spectra were recorded on
a Bruker Avance AV400 NMR spectrometer at 30 C. Chemical shifts
are reported in d units (ppm) relative to either TMS or the residual
solvent signal. IR spectra were recorded as KBr discs on a Perkin-
Elmer 298 spectrophotometer. HRMS was performed using a
Thermo Scientiﬁc LTQ Orbitrap XL at the EPSRC UK National Mass
Spectrometry Facility at Swansea University. Melting points (un-
corrected) were determined on a Gallenkamp melting point
apparatus in open glass capillary tubes. TLC was performed on
Merck Silica Gel 60F254 coated plates. Plates were visualised under
UV light (254/366 nm) and stained with either 2, 4-
dinitrophenylhydrazine, iodine or phosphomolybdic acid. Fluka
silica gel 60 (30-45m) was used for ﬂash chromatography. Elemental
analyses (C, H, N) was carried out by Warwick Analytical Services
using a CE440 elemental analyser. Results were within ±0.4% of the
theoretical values.
5.1.2. 1, 5-Di(3-bromophenyl)-3-(3-pyridyl)pentane-1,5-dione (7)
Sodium hydroxide solution (0.8 mL, 50% w/v, 10.00 mmol) was
added to a stirred and cooled (ice bath) solution of 3-
bromoacetophenone (0.40 mL, 5.00 mmol) in ethanol (2.5 mL). 3-
Pyridinecarboxylate (0.47 mL, 5.00 mmol) was added and stirring
continued for 2 h before allowing the reaction to warm to RT. On
the formation of a cream precipitate the reaction was quenched
with water (30 mL) and the solid removed by ﬁltration. After
washing with water the solid was recrystallized from ethanol
affording white crystals (0.305 g, 25%). mp 152e154 C; 1H NMR
(CDCl3): d 3.32 (2H, dd, J ¼ 6.6, 16.7 Hz), 3.54 (2H, dd, J ¼ 6.6,
16.7 Hz), 4.08 (1H, quin, J ¼ 6.6 Hz), 7.15e7.26 (2H, m), 7.36 (2H, t,
J ¼ 8.3, Hz), 7.60e7.70 (2H, m), 7.86 (2H, d, J ¼ 8.3 Hz), 8.07 (2H, s),
8.48 (1H, d, J ¼ 1.2 Hz), 8.59 (1H, s); 13C NMR (CDCl3) d 34.2, 44.2,
123.1, 123.5, 126.6,130.3,131.2, 135.4136.3,138.3,138.9,148.4,149.2,
Table 1
Antitrypanosomal activity and cytotoxicity of synthesized chalcones.
N Ar (A-ring) Ar' (B-ring) IC50/mM SIb
T. b. rhodesiense STIB900a Cytotoxicity
KB Cells
7 e e 12.2 181 15
8 3-Py- 3-Br-Ph- 0.29 13.5 47
9 Ph- 3-Br-Ph- 0.96 18.4 19
10 3-Py- Ph- 0.72 7.7 11
11 3-Py- 3-MeO-Ph- 0.41 2.3 6
12 3-Py- 4-Br-Ph- 0.34 7.9 23
13 3-Py- 2-Br-Ph- 37.8 >300 >8
14 3-Py- 2-MeO-Ph- 1.14 22.7 20
15 3-Py- 4-MeO-Ph- 0.94 21.7 23
16 3-Py- 3,4-(MeO)2-Ph- 0.98 22.8 24
17 4-Py- 3-Br-Ph- 0.65 23.7 36
18 2-Py- 3-Br-Ph- 0.40 14.7 37
19 3-Br-Ph- 3-Py- 0.69 43.7 63
20 3-Py- 3-Cl-Ph- 0.62 12.7 21
21 3-Py- 3,4-(OCH2O)-Ph- 4.83 59.4 12
22 3-Py- 3,4-F2-Ph- 0.72 20.7 29
23 3-Py- 3-HO-Ph- 1.15 21.7 19
24 3-Py- 3-Py- 1.02 17.0 17
Pentamidine 0.011 e e
Melarsoprol 0.005 e e
Podophyllotoxin e 0.058 e
a Values are the mean of two independent experiments in triplicate.
b Selectivity index (SI) ¼ IC50 KB cells/IC50 T. b. rhodesiense STIB900.
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196.4; IR (KBr)/cm1 1678 (C]O); HRMS found [Mþ1]þ 485.9686,
C22H17Br2NO2 requires [Mþ1]þ 485.9699; Anal. Calcd
C22H17Br2NO2: C, 54.24; H, 3.52, N, 2.88; Found C, 54.08; H, 3.54; N,
2.91.
5.1.3. General method for chalcone synthesis
Lithium hydroxide monohydrate (0.63 g, 14.95 mmol) was
added to a stirred solution of the appropriate aldehyde (9.35mmol)
and ketone (9.35 mmol) in 1,4-dioxane (2.5 mL) at RT. Upon
completion, as indicated by the formation of a precipitate and
conﬁrmed by TLC the reaction was quenched with water (30 mL).
The resulting mixture was extracted with ethyl acetate (3 30mL).
The combined organic extracts were washed with brine (50 mL),
dried (MgSO4) and the solvent removed under vacuum. The crude
product was puriﬁed by either recrystallization from ethanol or
ﬂash chromatography on silica gel.
5.1.4. (E)-1-(3-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-one (8)
Recrystallization from ethanol. Pale yellow crystals (80%). mp
126e128 C; 1HNMR (DMSO-d6): d 7.51 (1H, dd, J¼ 7.4, 3.9 Hz), 7.56
(1H, t, J ¼ 7.7 Hz), 7.81 (1H, d, J ¼ 15.8 Hz), 7.87e7.92 (1H, m), 8.11
(1H, d, J ¼ 15.8 Hz), 8.16e8.19 (1H, m), 8.35e8.42 (2H, m), 8.64 (1H,
dd, J ¼ 2.1, 7.4 Hz), 9.06 (1H, d, J ¼ 2.8 Hz); 13C NMR (DMSO-d6)
d 122.4, 123.4, 123.9, 127.6, 130.37, 131.04, 135.31, 135.96, 139.27,
141.4, 150.5, 151.2, 187.7; IR (KBr)/cm1 1665 (C]O); HRMS found
[M]þ 288.0025, C14H10BrNO requires [M]þ 288.0019; Anal. Calcd
C14H10BrNO: C, 58.36; H, 3.50, N, 4.86; Found C, 58.26; H, 3.44; N,
4.83.
5.1.5. (E)-1-(3-Bromophenyl)-3-(phenyl)prop-2-en-1-one (9)
Recrystallization from ethanol. Pale yellow crystals (67%). mp
82e84 C; 1H NMR (DMSO-d6): d 7.44e7.47 (3H, m), 7.53 (1H, t,
J ¼ 9.2 Hz), 7.76 (1H, d, J ¼ 15.3 Hz), 7.84e7.90 (3H, m), 7.93 (1H, d,
J ¼ 15.3 Hz), 8.14 (1H, dd, J ¼ 1.2, 7.5 Hz), 8.30e8.34 (1H, m); 13C
NMR (DMSO-d6) d 121.6,122.1,127.6,128.1,128.9,130.5,130.9,139.5,
187.8; IR (KBr)/cm1 1661 (C]O); HRMS found [Mþ1]þ 288.0048,
C15H11BrO requires [Mþ1]þ 288.0046; Anal. Calcd C15H11BrO: C,
62.74; H, 3.86; Found C, 62.38; H, 3.87.
5.1.6. (E)-1-(Phenyl)-3-(3-pyridinyl)prop-2-en-1-one (10)
Flash chromatography, 40% ethyl acetate: hexane. Lemon yellow
solid (67%). mp 93e95 C; 1H NMR (CDCl3): d 7.36 (1H, dd, J ¼ 4.9,
9.9 Hz), 7.49e7.56 (2H, m), 7.58e7.64 (2H, m), 7.79 (1H, d,
J ¼ 14.8 Hz), 7.91e7.97 (1H, m), 8.00e8.07 (2H, m), 8.63 (1H, dd,
J ¼ 1.0, 4.9 Hz), 8.62 (1H, d, J ¼ 1.0 Hz); 13C NMR (CDCl3) d 123.8,
128.6, 130.7, 132.9, 133.2, 134.6, 137.7, 140.9, 150.0, 151.1, 189.8; IR
(KBr)/cm1 1660 (C]O); HRMS found [Mþ1]þ 210.0913, C14H11NO
requires [Mþ1]þ 210.0913; Anal. Calcd C14H11NO: C, 80.36; H, 5.30,
N, 6.69; Found C, 80.36; H, 5.26; N, 6.60.
5.1.7. (E)-1-(3-Methoxyphenyl)-3-(3-pyridinyl) prop-2-en-1-one
(11)
Flash chromatography, 50% ethyl acetate: hexane. Light yellow
solid (70%). mp 83e84 C; 1H NMR (CDCl3): d 3.90 (3H, s), 7.15 (1H,
dd, J ¼ 3.7, 8.8 Hz), 7.36 (1H, dd, J ¼ 4.7, 8.8 Hz), 7.43 (1H, t,
J ¼ 8.4 Hz), 7.54e7.63 (3H, m), 7.79 (1H, d, J ¼ 15.8 Hz), 7.93e7.98
(1H, m), 8.64 (1H, dd, J ¼ 1.9, 4.7 Hz), 8.87 (1H, d, J ¼ 2.7 Hz). 13C
NMR (CDCl3): d 55.5, 112.9, 119.6, 120.8, 121.3, 123.8, 129.7, 130.7,
139.1, 140.9, 150.3, 151.1, 160.0, 189.5; IR (KBr)/cm1 1663 (C]O);
HRMS found [Mþ1]þ 240.1019, C15H13NO2 requires [Mþ1]þ
240.1019; Anal. Calcd C15H13NO2: C, 75.30; H, 5.48, N, 5.85; Found C,
75.53; H, 5.42; N, 5.67.
5.1.8. (E)-1-(4-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-one (12)
Recrystallization from ethanol. Fine off white crystals (80%). mp
126e128 C; 1H NMR (CDCl3): d 7.36 (1H, dd, J ¼ 5.3, 9.5 Hz), 7.54
(1H, d, J ¼ 15.9 Hz), 7.65 (2H, d, J ¼ 8.4 Hz), 7.80 (1H, d, J ¼ 15.8 Hz),
7.89 (2H, d, J ¼ 8.4 Hz), 7.93e7.98 (1H, m), 8.65 (1H, d, J ¼ 3.1 Hz),
8.86 (1H, s); 13C NMR (CDCl3): d 123.2, 123.8, 128.3, 130.1, 130.5,
131.8, 134.6, 141.5, 150.1, 151.3, 188.7; IR (KBr)/cm1 1663 (C]O);
HRMS found [Mþ1]þ 289.9997, C14H10BrNO requires [Mþ1]þ
289.9998; Anal. Calcd C14H10BrNO: C, 58.36; H, 3.50, N, 4.86; Found
C, 58.34; H, 3.46; N, 4.81.
5.1.9. (E)-1-(2-Bromophenyl)-3-(3-pyridinyl)prop-2-en-1-one (13)
Recrystallization from ethanol. Pale yellow crystals (37%). mp
248e250 C (decomposed); 1H NMR (CDCl3): d 7.38e7.42 (2H, m),
7.52 (1H, d, J ¼ 15.6 Hz), 7.67 (1H, dd, J ¼ 2.2, 5.4 Hz), 7.79 (1H, d,
J ¼ 15.6 Hz), 7.93e8.14 (2H, m), 8.15 (1H, t, J ¼ 7.2 Hz), 8.65 (1H, d,
J¼ 4.7 Hz), 8.87 (1H, s); 13C NMR (CDCl3): d 123.1, 127.0, 130.3, 131.6,
134.6,136.0,139.5,141.8,150.2,151.4,186.1; IR (KBr)/cm11666 (C]
O); HRMS found [Mþ1]þ 289.9999, C14H10BrNO requires [Mþ1]þ
289.9998; Anal. Calcd C14H10BrNO: C, 58.36; H, 3.50, N, 4.86; Found
C, 58.30; H, 3.42; N, 4.88.
5.1.10. (E)-1-(2-Methoxyphenyl)-3-(3-pyridinyl)prop-2-en-1-one
(14)
Recrystallization from ethanol. Pale yellow crystals (44%). mp
91e93 C; 1H NMR (DMSO-d6): d 3.91 (3H, s), 7.02 (1H, d, J¼ 8.3 Hz),
7.07 (1H, t, J ¼ 7.5 Hz), 7.35 (1H, dd, J ¼ 4.2, 7.9 Hz), 7.48e7.54 (1H,
m), 7.50 (1H, d, J ¼ 15.8 Hz), 7.64 (1H, d, J ¼ 15.8 Hz), 7.67 (1H, dd,
J ¼ 1.7, 7.5 Hz), 7.89 (1H, d, J ¼ 7.9 Hz), 8.61 (1H, d, J ¼ 4.2 Hz), 8.82
(1H, s); 13C NMR (CDCl3): d 55.5, 11.4, 120.7, 123.5, 128.7130.4, 130.6,
133.5, 134.7, 138.9, 149.9, 150.8, 158.3, 192.1; IR (KBr)/cm1 1656
(C]O); HRMS Found [Mþ1]þ 240.1017, C15H13NO2 requires [Mþ1]þ
240.1019; Anal. Calcd C15H13NO2: C, 75.30; H, 5.48, N, 5.85; Found C,
75.14; H, 5.58; N, 5.64.
5.1.11. (E)-1-(4-Methoxyphenyl)-3-(3-pyridinyl)prop-2-en-1-one
(15) [12]
Recrystallization from ethanol. Yellow solid (60%). mp
105e106 C; 1H NMR (CDCl3): d 3.90 (3H, s), 7.00 (2H, d, J ¼ 8.8 Hz),
7.35 (1H, dd, J ¼ 4.6, 8.3 Hz), 7.61 (1H, d, J ¼ 16.2 Hz), 7.78 (1H, d,
J¼ 16.2 Hz), 7.92e7.96 (1H, m), 8.04 (2H, d, J¼ 8.8 Hz), 8.62 (1H, dd,
J ¼ 4.2, 1.3 Hz), 8.87 (1H, d, J ¼ 2.5 Hz); 13C NMR (CDCl3): d 55.6,
114.0, 123.8, 130.7, 130.9, 134.6, 137.4, 140.1, 149.9, 150.9, 163.7,
188.0; IR (KBr)/cm1 1662 (C]O); HRMS found [Mþ1]þ 240.1017,
C15H13NO2 requires [Mþ1]þ 240.1019; Anal. Calcd
C15H13NO2.0.15H2O: C, 74.46; H, 5.54, N, 5.79; Found C, 74.41; H,
5.43; N, 5.77.
5.1.12. (E)-1-(3, 4-Dimethoxyphenyl)-3-(3-pyridyl)prop-2-en-l-one
(16)
Flash chromatography, 60e80% ethyl acetate: hexane. Light
yellow solid (67%). mp 91e93 C; 1H NMR (CDCl3): d 3.99 (6H, s),
6.94 (1H, d, J ¼ 7.5 Hz), 7.36 (1H, dd, J ¼ 5.0, 8.0 Hz), 7.63 (1H, d,
J¼ 15.9 Hz), 7.64 (1H, d, J¼ 2.0 Hz), 7.68 (1H, dd, J¼ 2.0, 7.5 Hz), 7.78
(1H, d, J ¼ 15.9 Hz), 7.93e7.96 (1H, m), 8.63 (1H, dd, J ¼ 1.5, 5.0 Hz),
8.87 (1H, d, J ¼ 1.5 Hz); 13C NMR (CDCl3) d 56.2, 110.0, 110.8, 122.7,
123.7, 124.5, 130.9, 134.6, 140.1, 149.40 149.9, 150.9, 153.7, 187.9; IR
(KBr)/cm11655 (C]O); HRMS found [Mþ1]þ 270.1125, C16H15NO3
requires [Mþ1]þ 270.1125; Anal. Calcd C16H15NO3: C, 71.36; H, 5.61,
N, 5.20; Found C, 71.03; H, 5.65; N, 5.14.
5.1.13. (E)-1-(3-Bromophenyl)-3-(4-pyridinyl)prop-2-en-1-one
(17)
Recrystallization from ethanol. Pale yellow crystals (34%). mp
104e106 C; 1H NMR (CDCl3): d 7.34 (1H, t, J ¼ 7.1 Hz), 7.41 (2H, d,
J ¼ 6.1 Hz), 7.53 (1H, d, J ¼ 15.6 Hz), 7.64 (1H, d, J ¼ 15.6 Hz),
7.66e7.69 (1H, m), 7.87 (1H, dt, J ¼ 1.0, 7.1 Hz), 8.07 (1H, t,
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J ¼ 1.0 Hz), 8.63 (2H, d, J ¼ 6.1 Hz); 13C NMR (CDCl3): d 122.1, 123.2,
125.4, 127.1, 130.4, 131.6, 136.2, 139.2, 141.8, 142.4, 150.7, 188.4; IR
(KBr)/cm1 1666 (C]O); HRMS found [Mþ1]þ 289.9998,
C14H10BrNO requires [Mþ1]þ 289.9998; Anal. Calcd C14H10BrNO: C,
58.36; H, 3.50, N, 4.86; Found C, 58.20; H, 3.46; N, 4.81.
5.1.14. (E)-1-(3-Bromophenyl)-3-(2-pyridinyl)prop-2-en-1-one
(18)
Recrystallization from ethanol. Pale yellow crystals (47%). mp
110e112 C; 1H NMR (CDCl3): d 7.40e7.49 (2H, m), 7.55 (1H, t,
J ¼ 8.8 Hz), 7.72 (1H, d, J ¼ 16.0 Hz), 7.85e8.00 (2H, m), 8.10e8.15
(2H, m), 8.20 (1H, s), 8.70 (1H, d, J ¼ 4.5 Hz); 13C NMR (CDCl3):
d 125.0, 126.9, 127.5, 130.9, 135.7, 137.2, 143.8, 150.1, 152.6, 188.3; IR
(KBr)/cm1 1664 (C]O); HRMS found [Mþ1]þ 289.0056,
C14H10BrNO requires [Mþ1]þ 289.0052; Anal. Calcd C14H10BrNO: C,
58.36; H, 3.50, N, 4.86; Found C, 58.30; H, 3.45; N, 4.86.
5.1.15. (E)-3-(3-Bromophenyl)-1-(3-pyridinyl)prop-2-en-1-one
(19)
Recrystallization from ethanol. Pale yellow crystals (40%). mp
114e116 C; 1H NMR (CDCl3): d 7.32e7.44 (2H, m), 7.52 (1H, d,
J ¼ 16.5 Hz), 7.72 (1H, d, J ¼ 6.5 Hz), 7.81 (1H, d, J ¼ 16.5 Hz),
7.93e7.98 (2H, m), 8.14 (1H, t, J ¼ 1.5Hz), 8.64 (1H, d, J ¼ 2.7 Hz),
8.87 (1H, s); 13C NMR (CDCl3): d 123.1, 123.2, 126.6, 130.4, 131.6,
134.6, 136.0, 142.3, 150.2, 151.4, 188.4; IR (KBr)/cm1 1658 (C]O);
HRMS found [Mþ1]þ 289.0055, C14H10BrNO requires [Mþ1]þ
289.0052; Anal. Calcd C14H10BrNO: C, 58.36; H, 3.50, N, 4.86; Found
C, 58.30; H, 3.45; N, 4.81.
5.1.16. (E)-1-(3-Chlorophenyl)-3-(3-pyridinyl)prop-2-en-1-one
(20)
Recrystallization from ethanol. Off white crystals (65%). mp
128e130 C; 1H NMR (CDCl3): d 7.37 (1H, dd, J ¼ 5.2, 7.7 Hz), 7.45
(1H, t, J ¼ 6.6 Hz), 7.51e7.60 (2H, m), 7.80 (1H, d, J ¼ 16.0 Hz), 7.89
(1H, d, J ¼ 7.6 Hz), 7.94e8.02 (2H, m), 8.65 (1H, d, J ¼ 5.2 Hz), 8.86
(1H, s); 13C NMR (CDCl3): d 123.1, 123.8, 126.6, 128.6, 130.1, 130.4,
133.0, 135.1, 139.3, 141.8, 150.2, 151.4, 188.4; IR (KBr)/cm11665 (C]
O); HRMS found [Mþ1]þ 244.0524, C14H10NOCl requires [Mþ1]þ
244.0524; Anal. Calcd C14H10NOCl: C, 69.00; H, 4.14, N, 5.75; Found
C, 68.86; H, 4.12; N, 5.66.
5.1.17. (E)-1-(3,4-Methylenedioxyphenyl)-3-(3-pyridinyl)prop-2-
en-1-one (21)
Recrystallization from ethanol. Off white crystals (55%). mp
138e140 C; 1H NMR (CDCl3): d 6.10 (2H, s), 6.92 (1H, d, J ¼ 7.8 Hz),
7.37 (1H, dd, J ¼ 4.3, 7.1 Hz) 7.54 (1H, d, J ¼ 2.1 Hz), 7.57 (1H, d,
J ¼ 14.9 Hz) 7.67 (1H, dd, J ¼ 2.1, 7.8 Hz), 7.78 (1H, d, J ¼ 14.9 Hz),
7.93e7.98 (1H, m), 8.63 (1H, dd, J ¼ 1.1, 4.3 Hz), 8.86 (1H, d,
J¼ 1.2 Hz); 13C NMR (CDCl3) d 102.0,108.0,109.4,123.5,123.8,124.9,
130.8, 132.5, 134.6, 140.4, 148.5, 149.9, 151.0, 152.0, 187.6; IR (KBr)/
cm1 1666 (C]O); HRMS found [Mþ1]þ 254.0811, C15H11NO3 re-
quires [Mþ1]þ 254.0812; Anal. Calcd C15H11NO3: C, 71.14; H, 4.38,
N, 5.53; Found C, 70.91; H, 4.36; N, 5.48.
5.1.18. (E)-1-(3,4-Diﬂuorophenyl)-3-(3-pyridinyl)prop-2-en-1-one
(22)
Recrystallization from ethanol. Pale green crystals (47%). mp
120e121 C; 1H NMR (DMSO-d6): d 7.50e7.53 (1H, m), 7.63e7.70
(1H, m), 7.78 (1H, d, J¼ 15.0 Hz), 8.10 (2H, d, J¼ 15.0 Hz), 8.24e8.29
(1H, m), 8.37e8.39 (1H, m), 8.64 (1H, dd, J¼ 1.5, 4.3 Hz), 9.05 (1H, d,
J¼ 1.2, 4.3 Hz); 13C NMR (DMSO-d6) d 117.9,118.1,123.1, 126.5,130.3,
134.7, 141.4, 150.5, 150.9, 186.5; IR (KBr)/cm1 1661 (C]O); HRMS
found [M]þ 246.0724, C14H9NOF2 requires [M]þ 246.0725; Anal.
Calcd C14H9F2NO: C, 68.57; H, 3.70, N, 5.71; Found C, 68.48; H, 3.70;
N, 5.66.
5.1.19. (E)-1-(3-Hydroxyphenyl)-3-(3-pyridinyl)prop-2-en-1-one
(23)
After quenching with water the mixture was acidiﬁed with 1 M
HCl before extraction with ethyl acetate. Recrystallization from
ethanol. Light yellow crystals (55%). mp 182e184 C; 1H NMR
(DMSO-d6): d 7.09 (1H, dd, J ¼ 2.1, 8.5 Hz), 7.39 (1H, t, J ¼ 7.7 Hz)),
7.48e7.51 (2H, m), 7.65 (1H, d, J ¼ 6.8 Hz), 7.75 (1H, d, J ¼ 14.9 Hz),
8.01 (1H, d, J ¼ 14.9 Hz), 8.33 (1H, d, J ¼ 7.7 Hz)), 8.62 (1H, s), 9.02
(1H, s), 9.85 (1H, brs, OH); 13C NMR (DMSO-d6) d 114.7, 119.7, 120.5,
123.9, 124.1, 129.9, 135.1, 138.7, 140.4, 150.3, 157.8, 188.9; IR (KBr)/
cm1 1660 (C]O); HRMS found [Mþ1]þ 226.0861, C14H11NO2 re-
quires [Mþ1]þ 226.0863; Anal. Calcd C14H11NO2: C, 74.65; H, 4.92,
N, 6.22; Found C, 74.51; H, 4.92; N, 6.03.
5.1.20. (E)-1-(3-pyridinyl)-3-(3-pyridinyl)prop-2-en-1-one (24)
Recrystallization from ethanol. Pale yellow crystals (41%). mp
148e150 C; 1H NMR (DMSO-d6): d 7.51 (1H, dd, J ¼ 4.8, 9.0 Hz),
7.62 (1H, dd, J ¼ 4.8, 9.0 Hz), 7.83 (1H, d, J ¼ 13.7 Hz), 8.12 (1H, d,
J¼ 13.7 Hz), 8.38 (1H, d, J¼ 7.2 Hz), 8.48 (1H, d, J¼ 7.2 Hz), 8.63 (1H,
d, J ¼ 4.8 Hz), 8.85 (1H, d, J ¼ 4.8 Hz), 9.06 (1H, s), 9.37 (1H, s); 13C
NMR (DMSO-d6) d 123.6, 123.9, 130.3, 132.5, 135.3, 141.3, 149.8,
151.3,153.5,188.3; IR (KBr)/cm11666 (C]O); HRMS found [Mþ1]þ
211.0864, C13H10N2O requires [Mþ1]þ 211.0866; Anal. Calcd
C13H10N2O: C, 74.27; H, 4.79, N, 13.33; Found C, 73.90; H, 4.79; N,
13.36.
5.2. Biological assays
5.2.1. Trypanocidal activity
Trypanosoma brucei rhodesiense STIB 900, a clone of a population
isolated in 1982 from a patient in Tanzania. Stock drug solutions
were prepared in DMSO at 20 mM and further diluted to the
appropriate concentration using medium. Assays were performed
in 96-well microtiter plates with each well containing 100 mL of
parasite culture (1  103 bloodstream forms) with serial drug di-
lutions at 37 C for 72 h in 5% CO2. Each compound was tested in
triplicate with 30 mg/mL the highest concentration of compound
used and a 3-fold serial dilution was performed down to a suitable
concentration to obtain an IC50 value. Control wells were without
drug and blanks were medium only. After 72 h of incubation the
plates were inspected to assure growth in control wells and to
determine the minimum inhibitory concentration (MIC). Subse-
quently, 20 mL of Alamar Blue™ was added to each well and the
plates incubated for another 2e4 h. Plates were read on a Gemini
Plate Reader (Molecular Devices) using an excitationwave length of
530 nm and an emission wave length of 580 nm (cut off 550 nm).
IC50 values were calculated using Prism © software. Pentamidine
and melarsoprol were used as positive controls.
5.2.2. Toxicity on KB cells
KB cells, derived from a human carcinoma of the nasopharynx
and typically used in assays for antineoplastic agents, were main-
tained in RPMI 1640 medium (Sigma, UK), 10% heat-inactivated
foetal calf serum, 37 C, 5% CO2. KB cell monolayers, prepared in
96-well plates, were exposed to the test compounds for 72 h.
Podophyllotoxin was used as a positive control. 20 mL of Alamar
Blue™was added to each well. After a further 2e4 h incubation the
plates were read (Molecular Devices Gemini™) at EX/EX 530/580,
cut-off 550 nm. The IC50 values were calculated by sigmoidal
regression analysis (Prism ©).
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